Strix

Strix Therapeutics is an early-stage biotechnology company focused on developing next-generation small molecule inhibitors for the treatment of cancer. The company specifically targets the DNA damage response (DDR) pathway, with a primary focus on inhibiting DNA-dependent protein kinase (DNA-PK), a critical enzyme in the non-homologous end joining (NHEJ) repair process. By inhibiting DNA-PK, Strix aims to sensitize tumor cells to DNA-damaging agents like radiation and chemotherapy, as well as exploit synthetic lethal vulnerabilities in specific genetic backgrounds. Founded by leading researchers in oncology and drug discovery, the company is advancing its pipeline to address unmet needs in solid tumors.